Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IEV407 alone or with endocrine therapy in advanced HR-positive/HER2-negative breast cancer
NL-OMON61608Phase 1Not yet recruiting
- Sponsor
- Novartis
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of IEV407 in breast cancer (2 arms), sponsored by Novartis. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
IEV407
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON61608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61608.